Pien Tze Huang Pharmaceutical Another Innovative Tumor Drug Approved for Clinical

Recently, Pien Tze Huang Pharmaceutical received the PZH2113 Capsule "Drug Clinical Trial Approval Notice" approved and issued by the State Drug Administration, and agreed to carry out clinical trials of this product. The product is a Class 1 innovative chemical drug with independent intellectual property rights of the company. It is intended to be used to treat relapsed/refractory non-Hodgkin's lymphoma mainly composed of diffuse large B- cell lymphoma (DLBCL).

DLBCL is the most common non-Hodgkin lymphoma, with about 30%-40% of patients relapsing and another 10% refractory. At present, there is no clear optimal treatment for relapsed/refractory DLBCL, and the existing treatments are ineffective or expensive. PZH2113 capsule adopts protein degradation technology, which is a revolutionary technology in the field of biomedicine in recent years, and has been listed as a key development object by the "14th Five-Year Plan for the Development of Pharmaceutical Industry. Non-clinical studies have shown that this product has good safety, druggability and clinical development value. According to the Cortellis database, there is no drug with the same target and adaptation disease at home and abroad on the market or in research, this product research and development progress ranks first at home and abroad.

Pien Tze Huang Pharmaceutical insists on inheriting the essence and keeping the right innovation. While focusing on the secondary development of advantageous varieties with Pien Tze Huang as the core, it strengthens the layout of research and development projects and explores the road of innovation, involving the research and development of new products such as innovative drugs of traditional Chinese medicine, classic famous prescriptions and innovative drugs of chemical drugs. In addition to this project, up to now, a total of 4 innovative drugs of traditional Chinese medicine and 3 innovative drugs of chemical drugs are under clinical research, and 2 innovative drugs of chemical drugs and 4 classic prescriptions are in the preclinical research stage, covering many therapeutic fields such as tumor, pain, mental nerve and so on.

Looking to the future, Pien Tze Huang Pharmaceutical will continue to adhere to the development concept of "keeping the integrity of innovation, stability and far-reaching", continue to layout innovation and transformation, take scientific and technological innovation as the lead, accelerate the formation of new quality productivity, and promote the company's high-quality development.